
Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target
Jazz Pharmaceuticals (JAZZ) Analyst Ratings
Bulls say
Jazz Pharmaceuticals is a strong player in the biopharmaceutical industry with a diverse portfolio of approved drugs and a promising pipeline of neuro assets. Their recent acquisitions and development of new treatments, coupled with potential for strong international sales, indicate potential for further growth. However, investors should also consider potential risks in the highly regulated and competitive biotechnology sector.
Bears say
Jazz Pharmaceuticals is experiencing strong quarterly revenue growth, indicating that the company is able to execute on its existing commercial business and exceed performance expectations. Risks to the company include potential erosion of its Xyrem franchise due to competition, slower growth on both the top and bottom line, and potential exposure to macro headwinds. The company's recent acquisition of GW Pharmaceuticals provides potential for future revenue growth, but materiality of ESG factors and changes in the market cannot be underestimated.
This aggregate rating is based on analysts' research of Jazz Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Jazz Pharmaceuticals (JAZZ) Analyst Forecast & Price Prediction
Start investing in Jazz Pharmaceuticals (JAZZ)
Order type
Buy in
Order amount
Est. shares
0 shares